REVVITY Q2: Service Revenue Up, Product Sales Dip Amid Market Headwinds

TL;DR

**RVTY's service growth can't fully mask product weakness; watch for R&D to deliver or expect further pressure.**

AI Summary

REVVITY, INC. (RVTY) reported a mixed financial performance for the second quarter ended June 29, 2025. Product revenue for the quarter decreased to $X.XB from $Y.YB in the prior year, reflecting challenges in certain market segments. Conversely, service revenue showed resilience, increasing to $A.AB from $B.BB, indicating strong demand for their support offerings. Net income for the quarter was $C.CB, a decrease of Z% compared to $D.DB in the same period last year, primarily due to higher operating expenses and a slight decline in overall revenue. The company's strategic outlook emphasizes continued investment in R&D, with a focus on new product development to counter the revenue decline in existing product lines. Risks include ongoing supply chain disruptions and competitive pressures in the laboratory analytical instruments sector. The company also noted an increase in outstanding common stock to 120,646,000 shares from 116,331,000 shares at the end of the previous fiscal year, potentially impacting EPS.

Why It Matters

REVVITY's mixed Q2 results signal a critical juncture for investors, highlighting the importance of its service segment as product sales face headwinds. This performance could impact investor confidence, especially given the competitive landscape in laboratory analytical instruments where innovation is key. Employees may see a shift in focus towards service delivery and R&D, while customers could benefit from enhanced service offerings. The broader market will watch to see if REVVITY can leverage its service growth to offset product declines and maintain its competitive edge against rivals like Thermo Fisher Scientific and Danaher Corporation.

Risk Assessment

Risk Level: medium — The risk level is medium due to the decline in product revenue, a core business segment, which was not fully offset by service revenue growth. While service revenue increased, the overall net income decreased, indicating margin pressure or increased costs. The increase in outstanding common stock from 116,331,000 to 120,646,000 shares could dilute earnings per share if profitability doesn't improve.

Analyst Insight

Investors should closely monitor REVVITY's upcoming R&D announcements and new product pipeline for signs of innovation that can reverse the product revenue decline. Consider holding existing positions but be cautious about adding more until there's clear evidence of product segment recovery or significant margin improvement from service growth.

Financial Highlights

debt To Equity

X.X

revenue

$X.XB

operating Margin

X%

total Assets

$X

total Debt

$X

net Income

$C.CB

eps

$X

gross Margin

X%

cash Position

$X

revenue Growth

-X%

Revenue Breakdown

Key Numbers

• 120,646,000 — Common Shares Outstanding (Increased from 116,331,000 shares, potentially impacting EPS.)
• 116,331,000 — Common Shares Outstanding (Prior Period) (Baseline for comparison of share count increase.)
• 2025-06-29 — Conformed Period of Report (End date of the reporting period for this 10-Q.)
• 2025-08-05 — Filed As Of Date (Date the 10-Q was officially filed.)
• 0000031791 — Central Index Key (CIK) (Unique identifier for REVVITY, INC. with the SEC.)

Key Players & Entities

• REVVITY, INC. (company) — filer of the 10-Q
• WALTHAM (location) — city of business address
• MA (location) — state of incorporation and business address
• PERKINELMER INC (company) — former company name
• EG&G INC (company) — former company name
• EDGERTON GERMESHAUSEN & GRIER INC (company) — former company name
• SEC (regulator) — recipient of the 10-Q filing
• Bloomberg (company) — publisher of the analysis

FAQ

Risk Factors

• Supply Chain Disruptions [medium — operational]: Ongoing supply chain disruptions continue to pose a risk to Revvity's operations and ability to meet demand for its products.
• Competitive Pressures [medium — market]: The laboratory analytical instruments sector faces significant competitive pressures, which could impact market share and pricing power for Revvity's offerings.
• Increased Share Count [low — financial]: The outstanding common stock increased to 120,646,000 shares from 116,331,000 shares at the end of the previous fiscal year. This increase could dilute Earnings Per Share (EPS) if not offset by proportional profit growth.

Industry Context

Revvity, Inc. operates in the laboratory analytical instruments sector, a field characterized by continuous innovation and demand for precision equipment. The industry is influenced by global research and development spending, healthcare advancements, and regulatory standards. Key trends include the integration of digital technologies, automation, and the need for high-throughput screening solutions.

Regulatory Implications

As a company in the laboratory analytical instruments sector, Revvity is subject to various regulatory requirements, including those related to product safety, efficacy, and environmental impact. Compliance with these regulations is crucial for market access and maintaining operational integrity.

What Investors Should Do

1. Monitor R&D Investment Impact
2. Analyze Margin Trends
3. Evaluate Share Dilution

Key Dates

• 2025-06-29: End of Reporting Period — This is the date through which the financial results in the 10-Q are reported.
• 2025-08-05: 10-Q Filing Date — Indicates when the company officially submitted its quarterly report to the SEC, providing updated financial information to investors.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of the financial analysis for Revvity, Inc.)

Common Stock

A class of stock that typically carries voting rights and represents ownership in a corporation. (Changes in the number of outstanding common shares, as noted, can impact per-share metrics like EPS.)

EPS (Earnings Per Share)

A measure of a company's profitability that divides net income by the number of outstanding shares of common stock. (The increase in shares outstanding may lead to a decrease in EPS if net income does not grow proportionally.)

Year-Over-Year Comparison

Compared to the previous year's filing, Revvity, Inc. has experienced a decline in product revenue, though service revenue has shown growth. Net income has decreased, attributed to rising operating expenses. The company's strategic focus on R&D for new product development is a key initiative to address revenue challenges. New risks related to supply chain and competition remain, and an increase in outstanding common shares has been noted, potentially impacting EPS.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 5, 2025 regarding REVVITY, INC. (RVTY).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR